Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Profound Medical (PROF) Consolidated Net Income (2023 - 2025)

Historic Consolidated Net Income for Profound Medical (PROF) over the last 3 years, with Q3 2025 value amounting to -$8.0 million.

  • Profound Medical's Consolidated Net Income rose 1482.11% to -$8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$40.0 million, marking a year-over-year increase of 4408.95%. This contributed to the annual value of -$28.4 million for FY2024, which is 251.68% up from last year.
  • Latest data reveals that Profound Medical reported Consolidated Net Income of -$8.0 million as of Q3 2025, which was up 1482.11% from -$15.7 million recorded in Q2 2025.
  • Profound Medical's Consolidated Net Income's 5-year high stood at $7.3 million during Q2 2023, with a 5-year trough of -$48.6 million in Q4 2023.
  • For the 3-year period, Profound Medical's Consolidated Net Income averaged around -$8.4 million, with its median value being -$6.9 million (2024).
  • Data for Profound Medical's Consolidated Net Income shows a peak YoY increase of 8856.28% (in 2024) and a maximum YoY decrease of 26941.03% (in 2024) over the last 5 years.
  • Profound Medical's Consolidated Net Income (Quarter) stood at -$48.6 million in 2023, then surged by 88.56% to -$5.6 million in 2024, then tumbled by 43.45% to -$8.0 million in 2025.
  • Its last three reported values are -$8.0 million in Q3 2025, -$15.7 million for Q2 2025, and -$10.7 million during Q1 2025.